So many new members of my team ⁦Lincoln School of Life Sciences⁩ ⁦Matthew Simmonds⁩ very exciting time with great projects !

So pleased to support NUH CRF, great opportunity to excel in our Region
nottinghamcrf.nihr.ac.uk/about/team/lea…

NIHR will spend an additional £30 million per year to significantly increase opportunities for healthcare professionals to include research in their careers.

We are working with NHS England to ensure the barriers to research careers are overcome.

nihr.ac.uk/news/extra-30m…

Determining how the Antagonistic Relationship Between CD47-CALR in MPN and MDS can be Manipulated to Enhance Current Therapeutic Outcomes & Increase Immune Surveillance at University of Lincoln on FindAPhD.com findaphd.com/phds/project/d…

Super discussion about importance of research and innovation with execs today and Prof Ciro Rinaldi Research & Innovation Professor Karen Dunderdale PhD RN Fiona Hamer she/her Katy Mooney Anita Cooper -will be bringing back to teams to discuss ideas

Challenges in Treating Myelofibrosis | VuMedi vumedi.com/video/challeng… via @vumedi

IONiS investigators meeting on my way ! Let’s improve PV patients outcome ! MPN_Hub MPN Voice

The potential of targeting mutant calreticulin with antibodies in MPNs youtu.be/suV9zGzx0T0 via YouTube

ULHT Research Delivery Team with Simon Archer led by Prof Ciro Rinaldi attending #EHA 2023 in Frankfurt for haematology clinical trial! Insightful, educative and great exposure! Research & Innovation NHS United Lincs #Sumitomo #Protagonist

Great team @protagonist trial yesterday. New treatment option for PV #EHA2023 . Always an honour to share room with Dr Hofmann and Naveen Pemmaraju, MD

#EHA2023 poster up ! Come and visit at 1003 !

#EHA2023 and from #ASCO2023 straight into EHA !!

CONGRESS | #ASCO23 | Poster
Ciro Rinaldi (Prof Ciro Rinaldi) of University of Lincoln, UK shared insights into the invitro effects of ruxolitinib and magrolimab reducing overall cell survival rate in CD34+ MF samples, and significantly increasing calreticulin expression
#MPN #MPN sm #medicalcongress

🚨🚨Headline results of SWOG S1826 showing that Nivolumab-AVD has better PFS than brentuximab vedotin-AVD in the upfront treatment of Hodgkin lymphoma, with less toxicity, a 🧵👇🏻

#ASCO23 #lymsm

Nivolumab-AVD new standard of care advanced Hodgkin ? #ASCO2023